1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (202) 626-4833
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma †‡
Article first published online: 11 JUL 2002
DOI: 10.1002/cncr.10647
Copyright © 2002 American Cancer Society
Additional Information
How to Cite
Samson, D. J., Seidenfeld, J., Schmitt, B., Hasselblad, V., Albertsen, P. C., Bennett, C. L., Wilt, T. J. and Aronson, N. (2002), Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma . Cancer, 95: 361–376. doi: 10.1002/cncr.10647
- †
This work was developed under contract with the Agency for Healthcare Research and Quality (AHRQ contract number 290-97-0015). The Blue Cross and Blue Shield Association Technology Evaluation Center is an Evidence-Based Practice Center of the AHRQ.
- ‡
Charles L. Bennett has received grants from Schering-Plough and Astra-Zeneca and has acted as a consultant for Schering-Plough.
Publication History
- Issue published online: 11 JUL 2002
- Article first published online: 11 JUL 2002
- Manuscript Accepted: 15 JAN 2002
- Manuscript Revised: 7 JAN 2002
- Manuscript Received: 9 MAY 2001
Funded by
- Schering-Plough
- Astra-Zeneca
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , Androgen Deprivation Therapy in Prostate Cancer: Focusing on Sexual Side Effects, The Journal of Sexual Medicine, 2012, 9, 3Direct Link:
- 2, Endocrine prevention and treatment of prostate cancer, Molecular and Cellular Endocrinology, 2012,
- 3, , , , , , , , , , , Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer, BJU International, 2012, 109, 12Direct Link:
- 4, , , , , The Long-term Results with Delayed-combined Androgen Blockade Therapy in Local or Locally Advanced Prostate Cancer, Japanese Journal of Clinical Oncology, 2012, 42, 6, 534
- 5, , , , , A comparison of androgen deprivation therapy versus surgical castration for patients with advanced prostatic carcinoma, Acta Pharmacologica Sinica, 2011, 32, 4, 537
- 6, , , , , , , Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?, BJU International, 2011, 108, 10Direct Link:
- 7, , , , , Clinical efficacy of primary combined androgen blockade for Japanese men with clinically localized prostate cancer unsuitable for local definitive treatment: a single institution experience, International Journal of Clinical Oncology, 2011, 16, 6, 630
- 8, , Evidence-based medicine: comparative analysis of luteinizing hormone-releasing hormone analogues in combination with external beam radiation and surgery in the treatment of carcinoma of the prostate, BJU International, 2011, 107, 8Direct Link:
- 9, , , , , Traditional Approaches to Androgen Deprivation Therapy, Urology, 2011, 78, 5, S485
- 10, , , , , , , , Cancer de la prostate et hormonothérapie : indications thérapeutiques de première ligne, Progrès en Urologie, 2010, 20, 2, 109
- 11, , , , , Cancer de la prostate localement avancé et hormonothérapie, Progrès en Urologie, 2010, 20, S68
- 12, , , Does the pharmacological class effect between the different luteinizing hormone releasing hormone analogues used in the treatment of prostate cancer have to be assumed?, Actas Urológicas Españolas (English Edition), 2010, 34, 9, 749
- 13, , , , , , Effect of Delayed Maximal Androgen Blockade Therapy for Patients with Advanced Prostate Cancer Who Fail to Respond to Initial Androgen Deprivation Monotherapy, Japanese Journal of Clinical Oncology, 2010, 40, 12, 1154
- 14, , , , Microsatellite instability as a marker of prognosis and response to therapy: A meta-analysis of colorectal cancer survival data, European Journal of Cancer, 2010, 46, 15, 2788
- 15, , , , , , , , Preclinical Evaluation of a Recombinant Anti-Prostate Specific Membrane Antigen Single-Chain Immunotoxin Against Prostate Cancer, Journal of Immunotherapy, 2010, 33, 3, 262
- 16, , , , , , Prise en charge des métastases osseuses du cancer de la prostate. À propos d’un cas, Progrès en Urologie, 2010, 20, S72
- 17, Quand est-ce que je propose un blocage androgénique complet ?, Progrès en Urologie - FMC, 2010, 20, 1, F2
- 18, , , Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease, Urologic Oncology: Seminars and Original Investigations, 2009, 27, 3, 251
- 19, , , , , Management of complications of androgen deprivation therapy in the older man, Critical Reviews in Oncology/Hematology, 2009, 70, 3, 235
- 20, , , , , , Prostate Specific Antigen Half-Time and Prostate Specific Antigen Doubling Time as Predictors of Response to Androgen Deprivation Therapy for Metastatic Prostate Cancer, The Journal of Urology, 2009, 181, 6, 2520
- 21, , , , , , Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts, The Journal of Steroid Biochemistry and Molecular Biology, 2009, 115, 3-5, 126
- 22
- 23, , , , Androgen deprivation therapy for prostate cancer, Expert Opinion on Pharmacotherapy, 2008, 9, 2, 211
- 24, Androgen receptor: role and novel therapeutic prospects in prostate cancer, Expert Review of Anticancer Therapy, 2008, 8, 9, 1495
- 25, , , , Androgendeprivation in der Therapie des Prostatakarzinoms, Der Urologe, 2008, 47, 3, 270
- 26
- 27, , , , Estrategias terapéuticas del cáncer de próstata de estadio T3, EMC - UrologÃa, 2008, 40, 1, 1
- You have free access to this content28, , , , , , , , , , , , Evidence-based Clinical Practice Guidelines for Prostate Cancer (Summary – JUA 2006 Edition), International Journal of Urology, 2008, 15, 1Direct Link:
- 29, , Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implications, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 2, 243
- 30, Maximal androgen blockade for advanced prostate cancer, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 2, 331
- 31
- 32, , , , , , , , , The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, BJU International, 2008, 102, 11Direct Link:
- 33, , , Undetectable Level of Prostate Specific Antigen (PSA) Nadir Predicts PSA Biochemical Failure in Local Prostate Cancer with Delayed-combined Androgen Blockade, Japanese Journal of Clinical Oncology, 2008, 38, 9, 617
- 34
- 35
- 36, , , , , , , , , , , , , , , , , , , Cancer de la prostate, Progrès en Urologie, 2007, 17, 6, 1159
- 37, , , , Cellular Changes in Prostate Cancer Cells Induced by Intermittent Androgen Suppression, European Urology, 2007, 52, 3, 725
- 38, Drug Insight: role of the androgen receptor in the development and progression of prostate cancer, Nature Clinical Practice Oncology, 2007, 4, 4, 236
- 39, , , , Effects of nonsteroidal antiandrogen agents on experimental esophageal carcinoma in rats, Esophagus, 2007, 4, 3, 111
- 40, , Goserelin acetate in combination with radiotherapy for prostate cancer, Expert Opinion on Pharmacotherapy, 2007, 8, 2, 257
- 41, Is hormone ablation still the right choice for advanced prostate cancer?, BJU International, 2007, 100,Direct Link:
- 42, , , , Luteinising hormone-releasing hormone antagonists in prostate cancer therapy, Expert Opinion on Emerging Drugs, 2007, 12, 2, 285
- 43, , Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer, PharmacoEconomics, 2007, 25, 4, 309
- You have free access to this content44, , , , Prostate-specific antigen half-life and pretreatment prostate-specific antigen: Crucial predictors for prostate-specific antigen trend in delayed-combined androgen blockade therapy, International Journal of Urology, 2007, 14, 3Direct Link:
- 45
- 46, , , , , , Androgen-deprivation therapy as primary treatment for localized prostate cancer, Cancer, 2006, 106, 8Direct Link:
- 47, Combined Androgen Blockade: An Update, Urologic Clinics of North America, 2006, 33, 2, 161
- 48, , , , , , , Deferred combined androgen blockade therapy using bicalutamide in patients with hormone-refractory prostate cancer during androgen deprivation monotherapy, BJU International, 2006, 97, 6Direct Link:
- 49, , Hormone Therapy for Prostate Cancer: Guidelines versus Clinical Practice, European Urology Supplements, 2006, 5, 3, 362
- 50, , , , , Hormone Therapy: Improving Therapy Decisions and Monitoring, European Urology Supplements, 2006, 5, 3, 369
- 51, , , Luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer: A review of their discovery, development, and place in therapy, Clinical Therapeutics, 2006, 28, 10, 1485
- 52, , , , , , , , Natural products as starting materials for development of second-generation SERCA inhibitors targeted towards prostate cancer cells, Bioorganic & Medicinal Chemistry, 2006, 14, 8, 2810
- 53, , , , , , Stepping-stones to the further advancement of androgen-deprivation therapy for prostate cancer, Expert Review of Anticancer Therapy, 2006, 6, 2, 259
- 54, , , , , , , , Vaccination therapy in prostate cancer, Cancer Immunology, Immunotherapy, 2006, 56, 4, 429
- 55, , Biochemical recurrence after definitive prostate cancer therapy. Part II: Treatment strategies for biochemical recurrence of prostate cancer*, Current Opinion in Urology, 2005, 15, 3, 187
- 56, , , , Cáncer de próstata avanzado, Medicine - Programa de Formación Médica Continuada Acreditado, 2005, 9, 27, 1772
- 57
- 58, , , , Hormone therapy and radiotherapy for early prostate cancer: A utility-adjusted number needed to treat (NNT) analysis, International Journal of Radiation Oncology*Biology*Physics, 2005, 61, 3, 687
- 59, , , , , , Is combined androgen blockade with bicalutamide cost-effective compared with combined androgen blockade with flutamide?, Urology, 2005, 66, 4, 835
- 60, Optimising Hormone Therapy in Advanced Disease, European Urology Supplements, 2005, 4, 8, 21
- 61, , , A re-assessment of the role of combined androgen blockade for advanced prostate cancer, BJU International, 2004, 93, 9Direct Link:
- You have free access to this content62, , , , , Combined androgen blockade in the management of advanced prostate cancer: A sensible or ostensible approach, International Journal of Urology, 2004, 11, 12Direct Link:
- 63, Endocrine treatment of prostate cancer, The Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 4, 287
- 64, How the Addition of Hormones Improves Outcome: Hormone Therapy Alone in Locally Advanced Prostate Cancer, European Urology Supplements, 2004, 3, 1, 22
- You have free access to this content65, , , , , , , , , , , Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results, International Journal of Urology, 2004, 11, 5Direct Link:
- 66, , Antiandrogen monotherapy for prostate cancer, Current Problems in Cancer, 2003, 27, 1, 45
- 67, , , Hormone therapy adjuvant to external beam radiotherapy for locally advanced prostate carcinoma, Cancer, 2003, 98, 11Direct Link:
- 68, , , , , , , , Prostate-Specific Antigen-Activated Thapsigargin Prodrug as Targeted Therapy for Prostate Cancer, JNCI Journal of the National Cancer Institute, 2003, 95, 13, 990
- 69, , Monotherapy versus combined androgen blockade in patients with advanced prostate cancer, Cancer, 2002, 95, 2Direct Link:
- 70, , , , Models for Prostate Cancer, The Cancer Handbook,Direct Link:
- 71, , Multidisciplinary Management of Genitourinary Malignancies, The Cancer Handbook,Direct Link: